INTRODUCTION
============

Alzheimer's disease (AD), a progressive neurodegenerative disease, is one of the most common forms of irreversible dementia. Patients with AD suffer from cognitive impairment including language problems, mood changes, as well as memory loss. AD brains display amyloid-beta (Aβ) plaques, tau tangles, synaptic degradation, and neuronal loss. Among these neurobiological changes, Aβ plaque is considered to be one of the major hallmarks of AD because of its early appearance during the progression of the disease. Therefore, a major focus of ongoing research has been identifying the mechanisms of Aβ plaque formation and aggregation to target Aβ metabolism ([@b62-molce-42-739]; [@b74-molce-42-739]). Although many studies and clinical trials for candidate drugs are currently underway, it is not yet clear how AD progresses, and no effective treatment for the disease exists. Currently-available drugs such as cholinesterase inhibitors only delay the onset of symptoms.

While early-onset AD pathology has been shown to be associated with genetic mutations in coding regions for proteins involved in Aβ metabolism (e.g., amyloid precursor protein; *APP*, presenilin 1 and 2; *PSEN1* and *PSEN2*), such mutations were not consistently observed in late-onset AD (LOAD), which comprises about 95% of patients; thus these cases have long been believed to be sporadic. However, recent genome-wide association studies revealed that compared to cognitively normal controls, several genetic variants are frequently observed in patients with LOAD, suggesting a strong association of these variants with late-onset cases ([@b45-molce-42-739]; [@b46-molce-42-739]). Genes that contain these genetic variants or are closely located to them are not those typically associated with Aβ generation or cleavage, rather these are genes that are associated with various cellular functions related to immune responses, endocytosis, and cholesterol metabolism ([@b38-molce-42-739]). Among identified genetic risk factors for LOAD, the most influential factor, for which the odds ratio is above 10 for homozygotes and found in about 40% of patients, is located on the *APOE* gene encoding apolipoprotein E ([@b16-molce-42-739]).

ApoE is an apolipoprotein that plays a major role in cholesterol transport. In the brain, ApoE was previously believed to be mainly produced by astrocytes ([@b91-molce-42-739]; [@b92-molce-42-739]). However, recent transcriptome analysis from human brain samples and hiPSC-derived brain cell types showed considerable expression of ApoE transcripts in microglia as well, and its expression is upregulated even in neurons in AD brains ([@b39-molce-42-739]; [@b49-molce-42-739]; [@b57-molce-42-739]; [@b90-molce-42-739]). There are three isoforms of ApoE; ApoE2, ApoE3, and ApoE4; only one or two amino acid variations differentiate these isoforms. ApoE3, the most common isoform present in about 78% of the population, has cysteine and arginine residues Cys112 and Arg158, whereas ApoE2 contains cysteine residues Cys112 and Cys158, and ApoE4 carries two arginine residues, Arg112 and Arg158. Although the difference is very subtle, it results in drastically differential effects on the risk for AD development. The allele frequency of ApoE2 is about 8%, and it is known to be neuroprotective. However, ApoE4 is one of the strongest risk factors for AD with a prevalence of about 14% ([@b51-molce-42-739]; [@b78-molce-42-739]). Since its strong association with AD was first reported about twenty-five years ago ([@b16-molce-42-739]; [@b78-molce-42-739]), many studies have been dedicated to determining how only one amino acid alteration in ApoE4 compared to ApoE3 could drastically increase the risk of AD ([@b51-molce-42-739]).

In terms of the role of ApoE protein on Aβ metabolism, contradictory data have been reported in different studies. Some studies have reported a decrease in Aβ plaque in familial AD (fAD) mouse models with ApoE deficiency, while others showed that ApoE is required for Aβ reduction, including astrocyte-mediated Aβ clearance, and deletion of ApoE accelerated the accumulation of fibrillar amyloid in the brains of fAD mice ([@b3-molce-42-739]; [@b30-molce-42-739]; [@b31-molce-42-739]; [@b40-molce-42-739]; [@b42-molce-42-739]; [@b79-molce-42-739]; [@b82-molce-42-739]). Regarding the role of ApoE isoforms in AD pathogenesis, most studies agree that ApoE4 induces the highest Aβ accumulation and gliosis compared with other isoforms ([@b49-molce-42-739]; [@b51-molce-42-739]; [@b52-molce-42-739]). Hyperphosphorylation of tau and related pathology (tauopathy), another hallmark of AD, has also been observed to be accelerated in the presence of the ApoE4 isoform ([@b75-molce-42-739]). However, the mechanisms of ApoE4-induced AD pathogenesis still remain unclear.

Recent evidence has emerged showing abnormal cholesterol metabolism by ApoE4 could mediate AD-associated pathology. Here, we review recent research, providing some insights on how ApoE4-mediated cholesterol dysregulation could affect functions of different brain cell types in the context of AD.

NEURONS
=======

Neurons are the most vulnerable to the toxicity of Aβ accumulation, and they are also the major cell type responsible for generating Aβ in the brain ([@b77-molce-42-739]; [@b92-molce-42-739]). Various pathological features are induced by Aβ accumulation in neurons, such as synaptic degradation, altered synaptic and neuronal circuit activity, and cell death, which have been extensively reviewed elsewhere ([@b8-molce-42-739]; [@b19-molce-42-739]; [@b63-molce-42-739]; [@b74-molce-42-739]). In this review, we focus on how ApoE4-induced cholesterol metabolic abnormalities could affect Aβ generation and alter the synaptic function in neurons.

Neuronal lipid rafts provide the platform for APP to encounter its cleaving enzymes, resulting in Aβ generation. Cholesterol is one of the major components of lipid rafts, and its dysregulation affects Aβ production in neurons ([@b25-molce-42-739]; [@b76-molce-42-739]). Tethering of cholesterol to methyl-β-cyclodextrin (MβCD) enables its delivery to the plasma membrane, and neurons treated with MβCD-cholesterol complex show increased lipid raft formation and generation of Aβ ([@b17-molce-42-739]; [@b54-molce-42-739]). However, it remains unknown whether cholesterol-dependent facilitation of Aβ cleavage is through the regulation of β-secretase activity or/and increased formation of APP/β-secretase clusters ([@b37-molce-42-739]; [@b53-molce-42-739]). Some genetic variants associated with the LOAD are found on or near genes related to cholesterol transport such as *APOE* and ATP-binding cassette transporter 7 (*ABCA7*), which implies that Aβ generation could be altered by these variants through cholesterol dysregulation and altered lipid raft formation ([@b38-molce-42-739]).

In the brain, cholesterol is mainly transmitted from astrocytes to neurons via lipoprotein particles, of which ApoE is one of the major components ([@b51-molce-42-739]; [@b84-molce-42-739]). ApoE, mainly produced by astrocytes, forms the lipoprotein complex with cholesterol and is secreted through the function of ABCAs. Among isoforms, ApoE4 displays lower transport affinity and binding capacity for lipids ([@b28-molce-42-739]; [@b84-molce-42-739]), which could reduce cholesterol transport from astrocytes to neurons. As a result, the formation of neuronal lipid rafts and Aβ production might be affected by ApoE4 in the brain. Two recent studies with astrocytes generated from hiPSCs addressed this point, and both showed higher accumulation of cholesterol in ApoE4-expressing astrocytes than in isogenic ApoE3 astrocytes ([@b49-molce-42-739]; [@b80-molce-42-739]). However, regarding the secretion of cholesterol from these ApoE4 astrocytes, [@b49-molce-42-739] showed increased extracellular cholesterol levels by directly measuring secreted cholesterol in cultured media, while [@b80-molce-42-739] speculated that ApoE4 astrocytes might secrete less cholesterol due to a reduction of ApoE and Abca1, which mediate the efflux of cholesterol. Further studies are required to directly examine cholesterol transport to neurons from astrocytes with different ApoE isoforms.

Although cholesterol synthesis in neurons is lower than in astrocytes, particularly in adults ([@b59-molce-42-739]; [@b68-molce-42-739]), ApoE isoform-dependent changes in cholesterol metabolism in neurons could also be driven in a cell-autonomous manner. For example, impaired efflux of cholesterol in ApoE4 neurons could contribute to its intracellular accumulation, leading to AD-related pathology, as observed in mice with cholesterol 24-hydroxylase-dependent cholesterol efflux suppressed in hippocampal neurons ([@b23-molce-42-739]). It is also important to investigate whether ApoE4 neurons have altered the expression and/or function of ApoE receptors such as those belonging to the low-density lipoprotein receptor family that can directly affect the uptake of extracellular cholesterol as well as Aβ clearance ([@b32-molce-42-739]).

Cholesterol plays critical roles in synaptic function. It helps maintain adequate curvature of membrane to facilitate soluble NSF attachment protein receptor (SNARE)-mediated membrane fusion. Depleting cholesterol significantly reduces synaptic transmission, which can be reversed by reloading cholesterol ([@b50-molce-42-739]; [@b81-molce-42-739]). Lack of cholesterol in neurons leads to impaired synaptic plasticity, evidenced by changes in paired-pulse facilitation and long-term potentiation ([@b43-molce-42-739]). Hippocampal synapses in mice with decreased astrocytic cholesterol secretion also showed fewer synaptic vesicles, more immature synapses, and reduced expression of presynaptic synaptosomal nerve-associated protein 25 (SNAP-25) required for the exocytic release of neurotransmitters ([@b83-molce-42-739]).

The role of ApoE isoforms on the formation of neuronal synapses and their function is not yet clear ([@b41-molce-42-739]). A recent study with ApoE2, ApoE3 and ApoE4 knock-in (KI) mice in which the murine *APOE* gene was replaced with the human *APOE*2, *APOE3* or *APOE4* gene showed that ApoE4 KI mice displayed reduced phagocytic capacity in astrocytes and increased senescence synapses compared to mice carrying other ApoE isoforms ([@b14-molce-42-739]). This result seems to be consistent with a study that demonstrated an increased number of synapses in hiPSC-derived neurons carrying *APOE4* alleles compared to ApoE3 neurons ([@b49-molce-42-739]). Nonetheless, further studies are necessary to understand the role of ApoE4-dependent cholesterol dysregulation in synaptic dysfunction and whether restoration of cholesterol metabolism in ApoE4 brain would be sufficient to recover from synaptopathy.

ASTROCYTES
==========

Lipoprotein-bound cholesterol from circulating plasma is prevented from entering the brain due to the presence of the blood-brain barrier (BBB), and astrocytes, which account for up to 40% of all brain cells in humans, are mainly responsible for producing cholesterol in the brain ([@b59-molce-42-739]; [@b92-molce-42-739]). Cholesterol synthesis in astrocytes is tightly regulated by an internal feedback loop; if the intracellular level of cholesterol is low, cholesterol synthesis is induced by increasing proteolytic processes of sterol regulatory element-binding proteins (SREBPs) and reducing levels of proteins that mediate cholesterol efflux ([@b5-molce-42-739]). When the intracellular cholesterol level is high, liver X receptor/retinoid X receptor (LXR/RXR)-mediated transcription for cholesterol transport proteins is increased, and efflux of lipoprotein complex is facilitated ([Fig. 1](#f1-molce-42-739){ref-type="fig"}). Cholesterol accumulation in ApoE4 astrocytes may not be due, solely, to impaired efflux resulting from reduced ApoE levels. Transcriptome analysis in hiPSC-derived astrocytes suggests the expression of genes involved in lipid metabolism is dysregulated in ApoE4 astrocytes, with an increase in the expression levels of cholesterol biosynthesis-related genes. Lysosomal cholesterol degradation processes also seem to be impaired in these cells ([@b49-molce-42-739]; [@b80-molce-42-739]). Further study is required to precisely elucidate the mechanisms underlying ApoE4-induced cholesterol accumulation in astrocytes, and how it can be targeted to resolve the abnormality.

Because cholesterol is a multifunctional metabolite, abnormal cholesterol metabolism by ApoE4 would lead not only altered cholesterol transport to other cell types but also functional deficits in astrocytes as observed in neurons ([@b27-molce-42-739]; [@b55-molce-42-739]) and microglia ([@b15-molce-42-739]; [@b69-molce-42-739]). However, there have not been many studies investigating the effects of intracellular cholesterol on cellular functions or formation of organelles in astrocytes. Therefore, investigating whether/how ApoE4 induces cholesterol-related cellular alterations in astrocytes are a priority. Cholesterol levels in astrocytes and glucose metabolism are closely linked ([@b26-molce-42-739]), A recent study showed ApoE isoform-dependent changes of brain glucose metabolism in mice ([@b88-molce-42-739]), and it suggests that cholesterol abnormalities caused by ApoE4 could alter glucose metabolism ([Fig. 1](#f1-molce-42-739){ref-type="fig"}). Since astrocytes provide not only structural but metabolic supports for neurons, further investigations of astrocyte-specific changes in glucose metabolism in humanized ApoE KI mouse models or single-cell type culture systems with different ApoE isoforms, and its association with cholesterol dysregulation are needed.

MICROGLIA
=========

The role of microglia in AD has been extensively investigated; nonetheless, their precise contribution to the development of AD pathology remains unclear. A recent development in single-cell transcriptome analysis technology revealed the spectrum of microglia phenotypes during AD pathogenesis and the species difference in transcriptomic information of disease-associated microglia between mice and humans ([@b39-molce-42-739]; [@b56-molce-42-739]; [@b57-molce-42-739]). Although this topic is of great interest, it is beyond the scope of this review. Nevertheless, it is important to note that in both mouse and human cells, ApoE, along with triggering receptor expressed on myeloid cells 2 (TREM2), is shown to be upregulated and mediates microglial phenotypic changes and recruitment to amyloid plaques during the progression of AD ([@b11-molce-42-739]; [@b39-molce-42-739]; [@b66-molce-42-739]; [@b82-molce-42-739]). Transition of microglia from resting (homeostatic) to reactive (disease-associated) phenotypes is generally mediated by transcriptional regulation ([@b21-molce-42-739]; [@b29-molce-42-739]; [@b44-molce-42-739]). Although ApoE isoform-dependent transcriptional regulation was recently suggested by multiple studies ([@b33-molce-42-739]; [@b49-molce-42-739]; [@b80-molce-42-739]), its precise mechanism is unclear.

Because excessive inflammatory response is associated with AD, the relationship between the level of cholesterol and immune responses in microglia, the brain resident macrophages, is of great interest. Interaction of cholesterol and inflammatory response in macrophages was suggested ([@b70-molce-42-739]). In microglia, however, regulation of inflammatory responses by peroxisome proliferator-activated receptor γ (PPARγ), LXR/RXR-mediated cholesterol synthesis, and phagocytic activity by PPARγ and LXR/RXR were reported in separate studies ([@b6-molce-42-739]; [@b18-molce-42-739]; [@b72-molce-42-739]; [@b73-molce-42-739]). Direct interaction between cholesterol and inflammatory responses in this cell type has not been assessed.

The effect of microglial cholesterol on AD pathogenesis has been previously investigated using primary cultured cells. In primary microglia, accumulation of intracellular cholesterol induced by either MβCD-mediated loading or Niemann--Pick disease, type C1 (NPC1) inhibition (thus blocking cholesterol export from the lysosome) also increases intracellular Aβ. Furthermore, a negative correlation between cholesterol accumulation-induced intracellular Aβ and ApoE levels in these cells was observed. These data suggest that ApoE contributes to intracellular Aβ clearance through the regulation of cholesterol levels in microglia ([@b47-molce-42-739]).

Recently developed protocols to generate microglia-like cells from hiPSC have enabled researchers to investigate functions and underlying mechanisms of ApoE4 variants in human microglia ([@b1-molce-42-739]; [@b58-molce-42-739]; [@b64-molce-42-739]). Microglia-like cells from hiPSC carrying the *APOE4* allele have fewer processes compared to isogenic cells with the *APOE3* allele, and live-imaging of Aβ-uptake assays and transcriptome analysis suggest impaired phagocytic activity as well as upregulation of immune responses in microglia by ApoE4 ([@b49-molce-42-739]). Interestingly, a recent study showed that glycolysis in microglia is important for acute response against Aβ ([@b2-molce-42-739]). The next several years will likely produce more exciting and important data elucidating the contribution of microglial cholesterol dysregulation by ApoE4 to the pathogenesis of AD.

OLIGODENDROCYTES
================

Oligodendrocytes have a unique structure called myelin that ensheathes axons, facilitating conduction of action potentials and protecting neurons from other possible extracellular insults ([@b24-molce-42-739]). Lipids are the major components of myelin membranes, consisting of at least 70% of their dry weight, whereas membranes in other cell types are generally composed of about 30% lipids and 70% proteins ([@b12-molce-42-739]; [@b34-molce-42-739]). This suggests that altered lipid composition by abnormal metabolic processes would affect not only intracellular compartments generally seen in other cell types but also the formation and function of myelin, which is critical for neuronal function.

Among lipid metabolites in myelin membranes, cholesterol has been shown to have a significant role in myelin formation. Inhibition of cholesterol-synthesizing ability in oligodendrocytes by deleting squalene synthases leads to a significant reduction of myelination in oligodendrocytes, inducing behavioral abnormalities such as ataxia and tremors in mice ([@b71-molce-42-739]). Increased levels of gene expression associated with cholesterol biosynthesis were also observed in oligodendrocyte lineage cells during the remyelination phase following axonal damage ([@b85-molce-42-739]). These data demonstrate the major contribution of oligodendrocyte-derived cholesterol for myelination in the brain. A recent study also reported the role of astrocytic cholesterol in the formation of myelin following axonal injury ([@b7-molce-42-739]). In this study, cell type-specific deletion of SREBP cleavage-activating protein (SCAP), which mediates cholesterol synthesis, either in oligodendrocytes or astrocytes, showed only partial impairment of myelination in mice. When SCAP is ablated in both cell types, however, mice showed an almost complete absence of myelination in the brain. These results suggest that altered levels of extracellular and intracellular cholesterol for oligodendrocytes could regulate myelination in the brain.

As a major cholesterol transporter, it would not be surprising that ApoE is involved in myelination processes. Indeed, a recent study showed that ApoE is required for cholesterol clearance in demyelinating lesions to prevent lysosomal accumulation of myelin debris ([@b9-molce-42-739]). Studies have found an association between amyloid pathology with myelin alteration in AD animal models and preclinical studies, including a reduction of myelination associated with brain atrophy ([@b20-molce-42-739]; [@b89-molce-42-739]). Further work is needed to determine the differential role of ApoE isoforms in oligodendrocytes and whether and how ApoE4-associated cholesterol dysregulation in these cells drive AD-associated pathology.

CONCLUSION
==========

Investigating pathological features of whole AD brain samples would be of interest. However, it is also necessary to tease out cell type-specific alterations and their contributions to AD pathogenesis. Recent investigations of cell type-specific functions of ApoE4 from various brain cell types isolated from ApoE KI mice or derived from hiPSC showed impaired cholesterol metabolism by ApoE4, specifically in glial cells that were not evident from previous studies that relied on bulk brain samples composed of mixed cell populations ([@b49-molce-42-739]; [@b61-molce-42-739]; [@b80-molce-42-739]). As we reviewed, cholesterol metabolism is closely linked to various functions in different types of cells in the brain, and its dysregulation can lead to AD-associated pathological phenotypes in each cell type, including Aβ upregulation in neurons, abnormal glucose metabolism in astrocytes, inflammatory responses in microglia, and myelination defects in oligodendrocytes ([Fig. 2](#f2-molce-42-739){ref-type="fig"}).

In addition to these cell types, the BBB, which is composed of various cell types, including pericytes and endothelial cells, was also shown to be influenced by ApoE4. Multiple studies suggest that ApoE4 leads to BBB leakage through the degeneration of pericytes and the disruption of the integrity of tight junctions ([@b10-molce-42-739]; [@b60-molce-42-739]), which leads to the accumulation of serum proteins in the brain ([@b4-molce-42-739]). This can result in further elevation of brain cholesterol. It is also possible that increased cholesterol in the brain or plasma by ApoE4 affects BBB integrity and may lead to leakage ([@b35-molce-42-739]; [@b36-molce-42-739]). While there is a close coupling between neurovascular dysfunction and AD, the cell types mentioned above are understudied in the context of AD. Exploring detailed mechanisms in BBB pathogenesis in ApoE4 brain may provide insights into a new therapeutic avenue.

While we largely discuss ApoE4 as an AD risk factor in terms of cholesterol metabolism in the brain, it is also important to mention that in several studies it has been suggested that plasma cholesterol level and AD risk/pathology are linked ([@b65-molce-42-739]; [@b86-molce-42-739]). Epidemiological studies show an increased concentration of plasma cholesterol in AD patients ([@b87-molce-42-739]), and diet-induced hypercholesterolemia in AD mouse models leads to increased Aβ and impaired memory ([@b67-molce-42-739]). Unlike physiological conditions in which the translocation of peripheral cholesterol to the brain is limited, it is facilitated when leakage of the BBB occurs under pathological conditions. Although more studies are necessary to identify plasma cholesterol as a causative factor, it is important to understand the dynamic relationship between brain cholesterol and plasma cholesterol in terms of AD pathogenesis.

Further studies are also required to determine whether other AD genetic risk factors associated with cholesterol homeostasis, including Clustrin (apolipoprotein J) and *ABCA7*, share pathological mechanisms with *APOE4*. In this regard, brain cholesterol may be targeted for therapeutic treatments in LOAD. Statins are β-hydroxy β-methylglutaryl-CoA (HMG-CoA) reductase inhibitors reducing the levels of cholesterol by blocking mevalonate synthesis. Statins including simvastatin which across the BBB have been tested in multiple studies and have demonstrated beneficial effects in various AD model systems ([@b13-molce-42-739]; [@b48-molce-42-739]). However inconsistent data regarding the effect of statins in clinical trials exist ([@b22-molce-42-739]; [@b87-molce-42-739]). Further clinical investigation with larger cohorts would provide more definitive insights into the effects of statins in AD. Alternatively, a cell type-specific approach or one that targets the signaling pathway that is affected by cholesterol dysregulation might be promising approaches for the development of novel therapeutics for AD.
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![Cholesterol homeostasis in astrocytes\
Intracellular cholesterol level is tightly regulated and maintained in astrocytes, major producers of cholesterol in the brain. When cholesterol level is low, SREBP-mediated cholesterol synthesis is triggered. If the level of cholesterol is increased, SREBP is suppressed and LXR/RXR-induced transcription for cholesterol transport proteins such as ApoE and Abca1 is facilitated. Cholesterol is also synthesized from glucose-derived Acetyl CoA, and the level of cholesterol can affect glucose metabolism.](molce-42-739f1){#f1-molce-42-739}

![Potential pathological role of cholesterol dysregulation by ApoE4 in different brain cell types\
Cholesterol dysregulation by ApoE4 could lead to cell type-specific functional abnormalities in the brain such as Aβ upregulation and impaired synaptic function in neurons, reduced synapse prunning activity in astrocytes, impaired remyelination in oligodendrocytes, and Aβ accumulation and inflammatory response in microglia.](molce-42-739f2){#f2-molce-42-739}
